Indian Institute of Integrative Medicine. Cancer Pharmacology Division (IIIM) ^{R&D Centre}

At CSIR-IIIM Jammu, the major focus of Cancer Pharmacology Division has been target specific novel small molecule modulator(s) from natural products, synthetic and semi-synthetic sources in an attempt to achieve the more potent preventive and chemotherapeutic effects. The goal in this effort is to maximize the therapeutic effects of inhibitors against deregulated isoforms specific to particular cancers under in vitro and in vivo conditions. Interest is growing in the posttranslational modifications that comprise mainly the evaluation of histone code and their relationship to cancer development and as therapeutic tool. The division has state of the art facilities for in vitro cytotoxicity studies against human cancer cell lines, in vivo anticancer studies against murine tumor models/human cancer xenograft/orthotropic models and target based in vitro mechanistic studies leading to the discovery of novel anti-cancer chemotherapeutics. Furthermore, human embryonic and cancer stem cell modulations by small molecule(s) are being explored lately for understanding regenerative and therapeutic aspects respectively.